Phase 2 clinical trial launched in Thailand to evaluate IL-15 agonist as therapy to reduce HIV reservoir

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva (also called N-803), administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.